Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.
Govt and industry fund health and biotech innovation in SEQ
The SEQ Innovation Economy Fund has awarded eight projects $94m in government funding, while...
Does the 2025–26 Budget do enough for science?
AAMRI has described the 2025–26 federal Budget as "very disappointing" for the...
Ming Long appointed Chair of CSIRO
Minister for Industry and Science Ed Husic has announced the appointment of Ming Long to the role...
